Neuralink: From 2 Patients to Global Trials
Neuralink expands from 2 PRIME study patients to international clinical trials across 4 countries.
Explore this event on the interactive timeline →After successfully implanting its second patient "Alex" in July 2024—who used the Link to play FPS games and design 3D CAD objects within days—Neuralink expanded beyond the initial PRIME study. By 2026, the company received FDA Breakthrough Device Designation for speech restoration and launched international trials in Canada, UAE, and the United Kingdom.
Key Numbers
- Patients Implanted
- 2+ (expanding)
- International Trials
- 4 countries
- New Application
- Speech Restoration
Verified Facts
- Patient 2 (Alex) began designing 3D objects in CAD software within 2 days of receiving the implant.
- Neuralink implemented mitigations for "thread retraction" issues seen in patient 1, reducing brain motion during surgery.
- The company received FDA Breakthrough Device Designation for its speech restoration application.
- International clinical trials expanded to Canada, UAE, and UK by 2026.